Skip to Content
Merck
CN
All Photos(3)

Documents

Safety Information

C0737

Sigma-Aldrich

Cilostazol

≥98% (HPLC), powder

Sign Into View Organizational & Contract Pricing
All Photos(3)
Synonym(s):
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal
Empirical Formula (Hill Notation):
C20H27N5O2
CAS Number:
73963-72-1
Molecular Weight:
369.46
MDL number:
MFCD00866780
UNSPSC Code:
41106305
PubChem Substance ID:
24278291
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: 10 mg/mL, clear

originator

Otsuka Pharma

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139) , PDE3B(5140)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

Application

Cilostazol has been used:
  • to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
  • in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
  • to induce adenosine triphosphate (ATP) release in white adipocytes

Biochem/physiol Actions

Phosphodiesterase III (PDE3) inhibitor

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361d

Hazard Classifications

Repr. 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial
Dawson DL, et al.
Circulation, 98(7), 678-686 (1998)
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
Money SR, et al.
Journal of Vascular Surgery, 27(2), 267-275 (1998)
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells
Munoz B, et al.
European Journal of Pharmacology, 616(1-3), 22-30 (2009)
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Molecular determinants of enterotoxigenic Escherichia coli heat-stable toxin secretion and delivery
Zhu Y, et al.
Infection and Immunity, 86(11), e00526-e00518 (2018)
View All Related Papers

Articles

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service